As part of the deal, McKesson as an entity will cease to own any part of Change and the company will give up its three seats on Change’s board of directors.
An administrative court on Wednesday ruled in favor of Biogen Inc in a battle with generic drugmaker Mylan NV over a patent on its multiple sclerosis drug Tecfidera. Biogen shares rose nearly 24% to $350 after the ruling. The Patent Trial and Appeal Board, an administrative court run by the U.S. Patent And Trademark Office, said Mylan had not demonstrated that some claims were patentable.
Bernie Sanders still may eke out a win in Iowa, and is the consensus front-runner in New Hampshire. But most venture capitalists investing in America's health care industry — the primary target of Bernie's ire — have shoved their heads so deep in the sand that they've found water.
CVS Health Corp.’s announcement Monday that former Aetna Inc. Chief Executive Mark Bertolini will leave the CVS board exposed tensions underlying one of the biggest U.S. health-care mergers. Mr. Bertolini joined the board after the pharmacy operator paid nearly $70 billion to buy the health insurer in 2018.
Hidden in the larger debate over “Medicare for all” is a fundamental economic question: Who pays for work-based health insurance? For the 157 million Americans who get health insurance through their work — or through the job of a spouse or parent — the answer may seem obvious, evident right on pay stubs. Employers pay most of it, and workers pay some.
No player received as much media-generated attention heading into Super Bowl LIV as Kansas City Chiefs quarterback Patrick Mahomes. All eyes were on him and, when it mattered most, the young signal-caller came through, bringing his team back from a 10-point deficit to win it all.